Long-acting injectables (LAIs)

Offering a long-acting injectable (LAI) for first-episode patients

June 19, 2020

Changing or switching a patient from a different long-acting injectable medication (LAI) to Invega Sustenna (paliperidone palmitate)

May 4, 2020

Changing or switching a patient from a different long-acting injectable (LAI) antipsychotic medication to Aristada

April 22, 2020

LAI Injection Frequency

March 24, 2020

LAI Injection Sites

March 23, 2020

Diminished Efficacy of an LAI Medication

March 16, 2020

Shared Decision Making

March 16, 2020

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

March 13, 2020

Clinical Indications

March 6, 2020

Oral Antipsychotics and LAIs

March 6, 2020

Transitioning a patient from risperidone oral to paliperidone palmitate (Invega Sustenna)

March 6, 2020

Deltoid Injection Side Effect Relief

March 6, 2020

Changing or switching a patient from a different long acting injectable medication (LAI) to Abilify Maintena

February 25, 2020

Long-acting Injectable (LAI) Antipsychotics are Available in the U.S.

February 7, 2020

What should clinicians know about Invega Trinza (paliperidone palmitate 12-week LAI)?

January 27, 2020

What should clinicians know about fluphenazine decanoate (“Prolixin Dec”)?

January 27, 2020

What should clinicians know about haloperidol decanoate (“Haldol Dec”)?

January 23, 2020

What should clinicians know about Aristada (aripiprazole lauroxil LAI)?

January 23, 2020

What should clinicians know about Abilify Maintena (aripiprazole monohydrate LAI)?

January 3, 2020

Considerations When Dosing Antipsychotic Medications

January 2, 2020